Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation

References

• Larocca A, Piaggio G, Podesta M, et al. Boost of CD34+- selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 2006;91(7):935–940.
   PubMed Web of Science ®Google Scholar
• Kong Y, Chang YJ, Wang YZ, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(10):1465–1473.
   PubMed Web of Science ®Google Scholar
• Carreras E, Dufour C, Mohty M, et al. The EBMT handbook hematopoietic stem cell transplantation and cellular therapies. 2019.
   Google Scholar
• Zhao Y, Gao F, Shi J, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(9):1898–1907.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Song J, Jiang Z, et al. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci. 2014;11(6):652–657.
   PubMed Web of Science ®Google Scholar
• Kong Y, Song Y, Hu Y, et al. Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget. 2016;7(21):30892–30906.
   PubMedGoogle Scholar
• Kong Y, Wang YT, Cao XN, et al. Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. J Transl Med. 2017;15(1):57.
   PubMed Web of Science ®Google Scholar
• Wang YT, Kong Y, Song Y, et al. Increased Type 1 immune response in the bone marrow immune microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(8):1376–1382.
   PubMed Web of Science ®Google Scholar
• Masouridi-Levrat S, Simonetta F, Chalandon Y. Immunological basis of bone marrow failure after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7(362).
   PubMed Web of Science ®Google Scholar
• Tan JLC, Wong E, Bajel A, et al. Severity of mucositis during allogeneic transplantation impacts post-transplant cyclosporin absorption. Bone Marrow Transplant. 2020;55(9):1857–1859.
   PubMed Web of Science ®Google Scholar
• Wong E, Mason K, Collins J, et al. Prognostic limitations of donor T cell chimerism after myeloablative allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2017;23(5):840–844.
   PubMed Web of Science ®Google Scholar
• Zaja F, Geromin A, Patriarca F, et al. Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. Am J Hematol. 2011;86(9):790–792.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• RCT. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019. Available from: https://www.R-project.org/.
   Google Scholar
• Zhao HY, Lyu ZS, Duan CW, et al. An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2018;182(5):679–692.
   PubMed Web of Science ®Google Scholar
• Shi MM, Kong Y, Song Y, et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood. 2016;128(25):2988–2999.
   PubMed Web of Science ®Google Scholar
• Chen J, Lipovsky K, Ellison FM, et al. Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood. 2004;104(6):1671–1678.
   PubMed Web of Science ®Google Scholar
• Delisle JS, Gaboury L, Belanger MP, et al. Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts. Blood. 2008;112(5):2111–2119.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Blazar BR. Acute graft-versus-host disease – biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167–2179.
   PubMed Web of Science ®Google Scholar
• van de Berg PJ, Heutinck KM, Raabe R, et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis. 2010;202(5):690–699.
   PubMed Web of Science ®Google Scholar
• Sinzger C, Digel M, Jahn G. Cytomegalovirus cell tropism. Curr Top Microbiol Immunol. 2008;325:63–83.
   PubMed Web of Science ®Google Scholar
• Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013;13(3):285–299.
   PubMed Web of Science ®Google Scholar
• Alchalby H, Yunus DR, Zabelina T, et al. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2016;51(9):1223–1227.
   PubMed Web of Science ®Google Scholar
• Bruns I, Lucas D, Pinho S, et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014;20(11):1315–1320.
   PubMed Web of Science ®Google Scholar
• Zhao M, Perry JM, Marshall H, et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat Med. 2014;20(11):1321–1326.
   PubMed Web of Science ®Google Scholar
• Garcia-Cadenas I, Rivera I, Martino R, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transplant. 2017;52(1):107–113.
   PubMed Web of Science ®Google Scholar
• Yu H, Tian Y, Wang Y, et al. Dendritic cell regulation of graft-vs.-host disease: immunostimulation and tolerance. Front Immunol. 2019;10(93)
   Google Scholar
• Ghobadi A, Fiala MA, Ramsingh G, et al. Fresh or cryopreserved CD34+-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(7):1072–1077.
   PubMed Web of Science ®Google Scholar
• Klyuchnikov E, El-Cheikh J, Sputtek A, et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 2014;20(3):382–386.
   PubMed Web of Science ®Google Scholar
• Askaa B, Fischer-Nielsen A, Vindelov L, et al. Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning. Bone Marrow Transplant. 2014;49(5):720–721.
   PubMed Web of Science ®Google Scholar
• Mainardi C, Ebinger M, Enkel S, et al. CD34(+) selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. Br J Haematol. 2018;180(1):90–99.
   PubMed Web of Science ®Google Scholar
• Stasia A, Ghiso A, Galaverna F, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1440–1443.
   PubMed Web of Science ®Google Scholar
• Alvarado LJ, Huntsman HD, Cheng H, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood. 2019;133(19):2043–2055.
   PubMed Web of Science ®Google Scholar
• Mahat U, Rotz SJ, Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(3):e65–e73.
   PubMedGoogle Scholar